- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01058629
Study to Evaluate the Clinical Performance of SynergEyes A2 Hybrid Contact Lenses
August 24, 2010 updated by: SynergEyes, Inc.
A 180 Day, Multicenter Study to Evaluate the Clinical Performance of SynergEyes A2 Hybrid Contact Lenses for Daily Wear Use in the Correction of Refractive Error With or Without Astigmatism in Non-diseased Eyes
This is a multicenter study to evaluate the clinical performance of the SynergEyes A2 lens in patients with refractive errors with or without astigmatism.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Hybrid contact lenses have been previously shown to be a safe and effective method to correct refractive errors with and without astigmatism.
The hybrid contact lens design may provide greater visual acuity and comfort than other soft or rigid gas permeable (RGP) lenses currently available.
The purpose of this study is to confirm the design of the SynergEyes A2 lens by evaluating clinical performance and, if necessary, modify certain lens parameters in order to optimize lens performance.
Objective and subjective parameters will be used to evaluate the lens.
Study Type
Interventional
Enrollment (Anticipated)
125
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Campbell, California, United States, 95008
- Family Eye Care Center
-
Carlsbad, California, United States, 92008
- SynergEyes, Inc.
-
Encino, California, United States, 91436
- Encino Optometric Center Corp.
-
San Diego, California, United States, 92129
- Carmel Mountain Vision Care
-
-
Michigan
-
East Lansing, Michigan, United States, 48823
- VisionCare Associates, PC
-
-
Missouri
-
St. Louis, Missouri, United States, 63144
- The Koetting Associates
-
-
New York
-
Penfield, New York, United States, 14526
- Eyesite
-
-
Tennessee
-
Brentwood, Tennessee, United States, 37027
- Primary Eyecare Group
-
-
Washington
-
Kirkland, Washington, United States, 98034
- Specialty Eyecare Group Totem Lake Vision Center
-
-
Wyoming
-
Laramie, Wyoming, United States, 82070
- Snowy Range Vision Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be able to understand and be willing to sign a written informed consent form
- Age ≥18 years
- Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specific appointments
- Have naturally occurring myopia up to -6.00 D or hyperopia up to +2.00 D (spectacle plane) with or without corneal astigmatism up to 6.00 D
- Be in good general health, based on his/her knowledge, including normal healthy eyes
- Possess wearable and visually functional eyeglasses
- Have manifest refraction visual acuity equal to or better than 20/25 in each eye
Exclusion Criteria:
- Subject requires multifocal vision correction or is wearing lenses in a monovision modality
- Subject has lenticular astigmatism uncorrectable by normal RGP tear layer optics
- Subject exhibits poor personal hygiene
- Subject is currently or within 30 days prior to enrollment in this study has been an active participant in another clinical study (except SynergEyes Protocol # SI 08-05)
- Subject is currently pregnant (to the best of the subject's knowledge), is planning a pregnancy within the next 9 months, or is lactating
- Subject has a known sensitivity to ingredients used in contact lens care products
- Subject has undergone refractive surgery or is currently receiving or has previously received orthokeratology treatment
- Subject is aphakic or pseudophakic
- Subject has ocular or systemic disease such as, but not limited to, anterior uveitis or iritis (past or present), glaucoma, Sjogren's Syndrome, lupus erythematosus, scleroderma, keratoconus, post surgical corneal irregularity or type II diabetes
- Subject is using ocular medications for any reason or systemic medications which might interfere with contact lens wear
- A known history of corneal hypoesthesia (reduced corneal sensitivity)
Slit lamp findings that would contraindicate contact lens wear, including, but not limited to:
- Evidence of corneal ulcer, corneal infiltrates or fungal infections
- Corneal scars within the visual axis
- Pterygium
- Dry eye symptoms with decrease tear levels and punctuate staining ≥ Grade 2
- Neovascularization or ghost vessels ≥1.5mm in from the limbus
- Seborrhoeic eczema or seborrhoeic conjunctivitis
- History of papillary conjunctivitis that has interfered with lens wear or a current condition of Grade 2 or greater
- Clinically significant (Grade 3 or 4) anterior segment abnormalities or any infection of the eye, lids or associated structures
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: SynergEyes A2 Hybrid Contact Lens
|
SynergEyes A2 is a hybrid contact lens cleared by the US Food and Drug Administration (FDA) for daily wear correction of up to +20.00 and -20.00 in eyes with astigmatism up to 6.00D and for presbyopia.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Confirm current SynergEyes A2 lens design by evaluating clinical performance using objective and subjective parameters
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Determine the best method for fitting the SynergEyes A2 hybrid contact lens
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Paul Kusy, OD, MS, FAAO, SynergEyes, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2009
Primary Completion (ANTICIPATED)
September 1, 2010
Study Completion (ANTICIPATED)
September 1, 2010
Study Registration Dates
First Submitted
January 26, 2010
First Submitted That Met QC Criteria
January 26, 2010
First Posted (ESTIMATE)
January 28, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
August 25, 2010
Last Update Submitted That Met QC Criteria
August 24, 2010
Last Verified
August 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SI 09-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractive Errors
-
Suzan A RattanCompletedRefractive Errors | Refractive SurgeryIraq
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityNot yet recruiting
-
Essilor InternationalCompletedRefractive Error | AmetropiaUnited States
-
London School of Hygiene and Tropical MedicineBritish Council for Prevention of Blindness; Tanzanian Society for the BlindCompletedUnder- and Uncorrected Significant Refractive ErrorsTanzania
-
Chulalongkorn UniversityNot yet recruitingRefractive Errors
-
Johnson & Johnson Vision Care, Inc.CompletedRefractive ErrorUnited States
-
Sun Yat-sen UniversityQueen's University, Belfast; Orbis; Aravind Eye Care System; Padmashree Dr. D.... and other collaboratorsCompleted
-
Asociación para Evitar la Ceguera en MéxicoTerminated
-
Alcon ResearchCompleted
Clinical Trials on SynergEyes A2 Hybrid Contact Lens
-
SynergEyes, Inc.CompletedHypersensitivity | Corneal DiseaseUnited States
-
Thomas A. Aller, ODSynergEyes, Inc.WithdrawnMyopia | Myopia, ProgressiveUnited States
-
CIBA VISIONCompleted
-
Bausch & Lomb IncorporatedCompleted
-
CooperVision, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Visioncare Research Ltd.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
CIBA VISIONUniversity of WaterlooCompleted
-
University of RochesterCompleted